Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP)(?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.

Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Transaction Date

Insider Name

Title

Buy/Sell

Number of Shares

Average Share Price

Total Transaction

Actions

12/17/2014

& Johnson Johnson

Major Shareholder

Sell

8,100

$7.62

$61,722.00

12/12/2014

& Johnson Johnson

Major Shareholder

Sell

5,000

$7.51

$37,550.00

12/10/2014

& Johnson Johnson

Major Shareholder

Sell

8,300

$7.72

$64,076.00

12/9/2014

& Johnson Johnson

Major Shareholder

Sell

5,000

$7.73

$38,650.00

12/8/2014

& Johnson Johnson

Major Shareholder

Sell

2,000

$7.69

$15,380.00

12/5/2014

& Johnson Johnson

Major Shareholder

Sell

15,900

$7.76

$123,384.00

12/1/2014

& Johnson Johnson

Major Shareholder

Sell

1,200

$7.54

$9,048.00

11/26/2014

& Johnson Johnson

Major Shareholder

Sell

2,000

$7.75

$15,500.00

11/24/2014

& Johnson Johnson

Major Shareholder

Sell

9,500

$8.14

$77,330.00

3/12/2014

Pfizer Inc

Major Shareholder

Buy

272,727

$11.00

$2,999,997.00

(Data available from 1/1/2013 forward)

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc., formerly Aquinox Pharmaceuticals (USA) Inc., is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1, which is a regulator of a cellular signaling pathway in immune cells, known as the PI3K pathway. Its lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125, it is advancing through Phase II development in several initial indications. The Company operates in Vancouver, British Columbia, Canada.